A revised treatment approach for hospitalized patients with eosinophilic and neutrophilicexacerbations of chronic obstructive pulmonary disease

dc.contributor.authorAksoy, Emine
dc.contributor.authorGungor, Sinem
dc.contributor.authorAgca, Meltem Coban
dc.contributor.authorOzmen, Ipek
dc.contributor.authorDuman, Dildar
dc.contributor.authorKocak, Nagihan Durmus
dc.contributor.authorAkturk, Ulku Aka
dc.contributor.authorTuncay, Eylem
dc.contributor.authorSalturk, Cuneyt
dc.contributor.authorYalcinsoy, Murat
dc.date.accessioned2019-07-04T10:06:32Z
dc.date.available2019-07-04T10:06:32Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVES: The choice of treatment according to the inflammation type in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) has been of recent interest. This study investigated the role of novel biomarkers, hospital outcomes, and readmission rates in the first month in patients with eosinophilic or neutrophilic AECOPD. MATERIALS AND METHODS: We conducted a retrospective observational cohort study in a Chest Teaching Hospital with hospitalized AECOPD patients. Subjects' characteristics, hemogram results, C-reactive protein (CRP), neutrophil/lymphocyte ratio (NLR), platelet/ lymphocyte ratio (PLR), platelet/mean platelet volume (PLT/MPV), length of hospital stay, mortality, and steroid use were recorded. Eosinophilic AECOPD defined as peripheral blood eosinophilia (PBE) was >2% and neutrophilic AECOPD as PBE Q%. Readmission within 28 days of discharge was recorded. RESULTS: Of 2727(31.5% females) patients, eosinophilic AECOPD was found in 510 (18.7%) patients. Leucocytes, CRF,' NLR, and PLR were significantly higher in neutrophilic AECOPD than in eosinophilic AECOPD (p<0.001). Steroid use and mortality rate were 45% and 0.6% in eosinophilic AECOPD and 71%, and 1.4% in neutrophilic AECOPD, respectively (p=0.001, p=0.19). Age >75 years, albumin <2.5 g/dL, CRP >50 mg/dL, and PLT/MPV <20x103 were found to be risks factors for hospital mortality (p<0.05 each). Readmission rates within 28 days of discharge were 5% (n=136), and this rate was higher in eosinophilic AECOPD patients not taking steroids (p<0.001). CONCLUSION: NLR, PLR, and CRP levels were higher in neutrophilic AECOPD compared with eosinophilic AECOPD. These markers decreased with treatment in neutrophilic AECOPD. A PLT/MPV ratio of <20x103 resulted in an increased mortality rate. Thus, appropriate steroid therapy may reduce readmission rates in the first 28 days after discharge in eosinophilic AECOPD.en_US
dc.identifier.citationAksoy, E. Gungor, S . Agca, MC. Ozmen, I. Duman, D. Kocak, ND. Akturk, UA . Tuncay, E. Salturk, C. Yalcinsoy, M. (2018). A revised treatment approach for hospitalized patients with eosinophilic and neutrophilicexacerbations of chronic obstructive pulmonary disease. Cilt:19.Sayı:4. 193-200 ss.en_US
dc.identifier.doi10.5152/TurkThoracJ.2018.18004en_US
dc.identifier.endpage200en_US
dc.identifier.issue4en_US
dc.identifier.startpage193en_US
dc.identifier.urihttps://hdl.handle.net/11616/12322
dc.identifier.volume19en_US
dc.language.isoenen_US
dc.publisherBılımsel tıp publıshıng house, bukres sokak no 3-20 kavaklıdere, ankara, 00000, turkeyen_US
dc.relation.ispartofTurkısh thoracıc journalen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPlatelet-lymphocyte ratıoen_US
dc.subjectcortıcosteroıd treatmenten_US
dc.subjectaırway ınflammatıonen_US
dc.subjectsputum-eosınophılıaen_US
dc.subjectblood eosınophılsen_US
dc.subjectcontrolled-trıalen_US
dc.subjectcopden_US
dc.subjectbıomarkersen_US
dc.subjectmortalıtyen_US
dc.subjectvolumeen_US
dc.titleA revised treatment approach for hospitalized patients with eosinophilic and neutrophilicexacerbations of chronic obstructive pulmonary diseaseen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
makale dosyası.pdf
Boyut:
190.63 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale dosyası
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.71 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: